There were no clinically suitable adjustments compared to 2011 except for new knowledge and new suggestions regarding the therapy with bisphosphonates and denosumab (see section ‘Bisphosphonates and RANKL Antibody Denosumab’). Within the INSEMA review – a prospectively randomized study comparing SLNE vs. no SLNE in individuals with early invasive https://ambroset010thr5.bcbloggers.com/profile